Company / Accounts Receivable
Aclaris Therapeutics, Inc. Accounts Receivable History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$318.0K
FY2024
5-year range
$298.0K / $623.0K
FY2020-FY2024
Trend
+6.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2024 after 3 years of decline, reaching $318,000.
Based on SEC 10-K filings.
$318,000 in FY2024 with a 5-year CAGR of -14.7%.
Declined from $484,000 to $318,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -20.1%
- 5-Year CAGR
- -14.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.7%, indicating a declining trend.
- In FY2024, accounts receivable increased 6.7% year-over-year.
- Peak accounts receivable was recorded in FY2020.
- Lowest accounts receivable in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $318.0K | +6.7% |
| FY2023 | $298.0K | -38.4% |
| FY2022 | $484.0K | -22.3% |
| FY2021 | $623.0K | -19.3% |
| FY2020 | $772.0K | +9.7% |
| FY2019 | $704.0K | +25.0% |
| FY2018 | $563.0K | +17.0% |
| FY2017 | $481.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026